MediWound Ltd. and PolyMedics Innovations announced an agreement for the promotion of NexoBrid in Germany, Austria, Belgium, the Netherlands anduxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL, NovoSorb BTM, and SUPRA SDRM. Along with MediWound's existing sales, marketing and medical teams' infrastructure, PMI plans to leverage its extensive customer access and commercial resources to drive increased utilization of NexoBrid in the specified regions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.24 USD | +3.28% | +15.66% | +79.35% |
Mar. 21 | MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 | CI |
Mar. 21 | Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.35% | 169M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- MDWD Stock
- News MediWound Ltd.
- MediWound Ltd. Announces Collaboration with PolyMedics Innovations for NexoBrid Distribution in Europe